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Abstract Micafungin, a clinically important echinocandin anti-
fungal drug, needs to be investigated as empirical therapy in
febrile neutropenia in comparison with azole compounds. A pro-
spective randomized study was conducted to compare clinical
outcomes between micafungin and intravenous itraconazole as
an empirical therapy for febrile neutropenia in hematological
malignancies. The antifungal drug (micafungin 100 mg or
itraconazole 200 mg IVonce daily) was given for high fever that
was sustained despite the administration of appropriate antibi-
otics. Treatment success was determined by composite end
points based on breakthrough invasive fungal infection (IFI),
survival, premature discontinuation, defervescence, and treat-
ment of baseline fungal infection. Duration of fever, hospital stay,
and overall survival (OS) were studied. A total of 153 patients
were randomized to receive micafungin or itraconazole. The
overall success rate was 7.1 % point higher in the micafungin
group (64.4 vs. 57.3%, p=0.404), satisfying the statistical criteria
for the non-inferiority of micafungin. The duration of fever and
hospital stay were significantly shorter in the micafungin group
(6 vs. 7 days, p=0.014; 22 vs. 27 days, p=0.033, respectively).
Grade 3 adverse events including hyperbilirubinemia (2 vs. 7),
elevation of transaminase levels (2 vs. 4), electrolyte imbalance
(1 vs. 2), atrial fibrillation (1 vs. 0), and anaphylaxis (1 vs. 0)
occurred in 7 and 13 patients in the micafungin (10.4 %) and
itraconazole (18.8 %) groups, respectively. Micafungin, when
compared with itraconazole, had favorably comparable success
rate and toxicity profiles on febrile neutropenia in patients with
hematological malignancies. In addition, it showed superior ef-
fect on shortening the hospital stay.
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Introduction
Febrile neutropenia (FN) is the most common and serious
complication that can occur during intensive chemotherapy
for patients with hematological malignancies [1, 2]. Since
the incidence of fungal infection can reach 24 % among pa-
tients with leukemia and the mortality from invasive aspergil-
losis is as high as 50 %, proper empirical antifungal therapy is
essential for patients with fever persisting despite initial
broad-spectrum antibacterial therapy [3–5].
For empirical use, the antifungal drug should be less toxic
than amphotericin B and more effective than the azole com-
pounds against Aspergillus and someCandida species other than
C. albicans. Echinocandins are considered one of the most ade-
quate compounds for empirical therapy because of their wide
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antifungal coverage and high efficacy against Aspergillus and
their excellent safety profile [6–8]. Micafungin is a novel
echinocandin that has shown activity against the Candida and
Aspergillus species by inhibiting the synthesis of 1,3-β-D-glucan,
an essential component of the fungal cell wall [9]. Micafungin
has shown its possible efficacy and safety as empirical therapy
for febrile neutropenic patients in non-randomized studies
[10–13]. In addition, micafungin may have an advantage over
azole-resistant Candida and Aspergillus species [14, 15]. In
Korea, itraconazole has been the only drug approved for empir-
ical antifungal therapy since 2005 despite increasing demands for
new antifungal empirical therapy. However, there has been no
controlled study comparing other antifungal agents with
itraconazole for empirical therapy among Koreans. Thus, in this
study, we prospectively compared clinical outcomes of
micafungin with intravenous itraconazole for empirical therapy
in febrile neutropenia following anticancer chemotherapy for he-
matological disorders.
Materials and methods
Study design
This prospective randomized study was conducted fromDecem-
ber 2012 through February 2014 at seven sites in South Korea.
This study was designed as a non-inferiority test to document
clinical outcomes of micafungin compared to those of
itraconazole. The institutional review board of each participating
institution approved this study design, and this study was con-
ducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from all patients before enroll-
ment. The study protocol was registered with the National Insti-
tutes of Health clinical trial registry at www.clinicaltrials.gov
(#NCT01344681).
Adult patients (age≥18 years) were included if they had grade
4 neutropenia (absolute neutrophil count ≤500/μL) and high fe-
ver (≥38.4 °C at any time or≥38.0 °C for 1 h by oral temperature)
resulting from intensive anticancer chemotherapy for acute leu-
kemia, highly aggressive lymphoma (Burkitt lymphoma, lym-
phoblastic lymphoma), or other hematological malignancies.
To be eligible, patients had to have persistent high fever against
proper broad-spectrum intravenous antibiotics for at least 72 h.
When patients met all the inclusion criteria, they were ran-
domly assigned, in a 1:1 ratio by block randomization, to receive
micafungin or itraconazole. Randomization was performed ac-
cording to disease, patient age, sex, and risk stratification (remis-
sion induction or salvage therapy, high risk; consolidation, low
risk). Subjects were automatically assigned by a pre-made ran-
dom code with a Web-based electronic system. The randomized
block design applied for the random code with risk stratification.
Administration of oral antifungal agents for prophylaxis prior to
the study was allowed.
Micafungin (Mycamine®, Astellas Pharma Tech Co.,
Ltd. Takaoka City, Japan) was administrated intravenous-
ly in normal saline at a dose of 100 mg over 60 min once
daily. Itraconazole (Sporanox®, Janssen-Cilag Ltd.,
Buckinghamshire, England) was administrated intrave-
nously at a dose of 200 mg twice daily for 2 days and then
200 mg once daily for 12 days. The minimum administra-
tion duration of the study drugs was 5 days. When the
patients recovered from granulocytic nadir without fever,
the empirical therapy was discontinued and treatment was
considered to have been completed. Persistent high fever
for 7 days after initiation of the antifungal drug was con-
sidered treatment failure, and a change in the assigned an-
tifungal drug was allowed based on the individual decision
of each investigator.
Efficacy and safety
The primary end point was the overall success rate. Therapy
was considered successful if the patient met all of the follow-
ing criteria: (1) did not have a breakthrough invasive fungal
infection (IFI); (2) survived for 7 days after therapy ended; (3)
no premature discontinuation because of adverse events or
lack of effects; (4) defervescence during granulocytic nadir;
and (5) successful treatment of any baseline fungal infection.
The breakthrough IFI was defined as proven or probable IFI
with onset of symptoms of an IFI on day 3 or later after
initiation of antifungal therapy following revised EORTC/
MSG criteria [16]. These five components were used to deter-
mine the overall response rate [17].
The secondary end points were duration of fever, dura-
tion of febrile neutropenia, duration of hospital stay, and
overall survival rate (OS). Toxicity profiles including
physical findings and laboratory data were recorded and
followed up until they were resolved using the National
Cancer Institute Common Toxicity Criteria version 3.0.
Statistical analysis
Analysis was based on an intention-to-treat approach from all
patients who underwent randomization. The non-inferiority of
micafungin in comparison with itraconazole was assessed and
the inferiority margin was 10 %. The sample size was calcu-
lated from previous independent studies for empirical
micafungin and itraconazole that had already shown response
rates as 61.7 and 47 %, respectively [13, 18]. A sample size of
154 patients was achieved with the type 1 and type 2 errors of
0.025 and 0.8, respectively. The overall response rate of the
antifungal agents was analyzed by Fisher’s exact test.
Overall survival, duration of fever, and duration of hospital
stay were assessed with the chi-square and log-rank tests.
The two-sided t test was applied for patient characteristics,
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and a p value of less than 0.05 was considered to indicate
statistical significance.
Results
Patient characteristics
A total of 153 patients were randomly assigned to the
micafungin (n=77) or itraconazole group (n=76). Among
them, 148 patients were treated with the study drugs (73 pa-
tients in the micafungin group and 75 patients in the
itraconazole group). The completion rates of treatment with
micafungin and itraconazole were 78.1 % (57/73) and 78.7 %
(59/75), respectively (Fig. 1). All of the patients were native
Koreans who received intensive anticancer chemotherapy for
various hematological malignancies, mainly for acute leuke-
mia. Sixty-three patients (86.3 %) were high-risk (remission
induction or salvage) in the micafungin group and 64 patients
(85.3 %) in the itraconazole group. Prophylactic antifungal
therapy was used in 50.7 % of the patients in the micafungin
group (fluconazole in 32 patients and itraconazole in 5) and
52.0 % in the itraconazole group (fluconazole in 34 patients
and itraconazole in 5) before the initiation of the study drug.
The median treatment duration of the study drug was 8 days in
both groups. Patient characteristics including gender, age, di-
agnosis, and risk stratification were balanced (Table 1).
Success rate
The outcomes of the five composite parameters are shown
in Table 2. There was no significant difference in each
composite parameter between the two groups. A total of
16 patients had baseline fungal infection documented with-
in 2 days from the initiation of study drugs (7 patients in
the micafungin group, 9 patients in the itraconazole group).
Four out of 7 patients (57.1 %) in the micafungin group
and 5 out of 9 patients (55.6 %) in the itraconazole group
have their documented fungal infection resolved with an-
tifungal therapy during the study. Documented organisms
and response are presented in Table 3. Breakthrough IFI
occurred in 3 patients in the micafungin group with one
proven IFI of Candida spp. and 2 probable cases. In the
itraconazole group, there were two proven IFI of
Aspergillus spp. and 3 probable cases. The overall success
rates of micafungin and itraconazole were 64.4 and 57.3 %,
respectively. The difference in the success rates (7.1 %)
was not statistically significant (p=0.404). Thus, these re-
sults satisfied non-inferiority criteria.
Defervescence, hospital stay, and overall survival
The median duration of fever in the micafungin and
itraconazole groups was 6.0 (95 % CI, 5–7) and 7.0
(95 % CI, 5–9) days, and the duration of fever was
Fig. 1 Flowchart of the study
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different between the two groups (p=0.014) (Fig. 2a). The
median duration of hospital stay in the micafungin group
and itraconazole group was 22 (95 % CI, 19–25) and 27
(95 % CI, 25–29) days, and the duration of hospitalization
was significantly lower in the micafungin group (p=
0.033) (Fig. 2b). The median OS in the micafungin group
and itraconazole group was 12.77 (95 % CI, 8.92–16.62)
and 9.27 (95 % CI, 5.27–13.27) months, respectively (p=
NS). In responding patients, the median duration of drug
delivery was 9.0 (95 % CI, 7–11) and 11.0 (95 % CI, 8–
14) days in the micafungin and itraconazole group,
respectively (p=NS).
Adverse events
All 153 patients who were in the intention-to-treat population
were included in the safety evaluation. The incidence and
severity of adverse events were similar between the two
groups (Table 4). Grade 3 hyperbilirubinemia, a well-known
common adverse event of antifungal drugs, was observed in 2
and 7 patients in the micafungin and itraconazole group,
respectively. Each case of atrial fibrillation and anaphylaxis
was observed in the micafungin group, and the events were
controlled with medications. Nine patients in the micafungin
group (12.3 %) and 16 patients in the itraconazole group
Table 2 Overall success rate
Parameter Micafungin (%) Itraconazole (%) p value
Overall success rate 47/73 (64.4) 43/75 (57.2) 0.404
1. No breakthrough fungal infectiona 70/73 (95.9) 70/75 (93.3) 0.719
2. Survived for at least 7 days after the end of therapy 67/73 (91.8) 67/75 (89.3) 0.780
3. No premature discontinuation for lack of efficacy or toxicity 50/73 (68.5) 49/75 (65.3) 0.729
4. Resolution of fever during neutropenia 49/73 (67.1) 45/75 (73.3) 0.473
5. Resolution of baseline fungal infection 4/7 (57.1) 5/9 (55.6) 1.000
a Breakthrough fungal infection: proven in 3 (Aspergillus spp. 2, Candida spp. 1) and probable in 5
Table 1 Patient characteristics
Micafungin
group (n=73)
Itraconazole
group (n=75)
p
value
Gender, n Male 42 40 0.624
Female 31 35
Age, years Mean (range) 49 (20–85) 49 (20–78) 0.749
Diagnosis, n (%) AML 45 (61.6) 43 (57.3) 0.926
ALL 19 (26.0) 20 (26.6)
NHL 5 (6.8) 6 (8.0)
Burkitt’s 2 2
Lymphoblastic 3 4
Others 4 (5.4) 6 (8.0)
MDS 3 4
CMML 1 0
MM 0 2
Underlying infection
(other than fungal), n (%)
Total 30 (41.0) 22 (29.3) 0.169
Bacterial 17 13
Viral 13 9
Treatment setting, n (%) Remission 44 (60.2) 41 (54.6) 0.629
Salvage 17 (23.3) 23 (30.7)
Consolidation 12 (16.4) 11 (14.7)
Antifungal prophylaxis, n (%) 37 (50.7) 39 (52.0) 0.869
Neutropenia duration, days Median (range) 16 (4–63) 15 (5–26) 0.676
Treatment duration, days Median (range) 8 (3–20) 8 (1–18) 0.452
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MDS
myelodysplastic syndrome, CMML chronic myelomonocytic leukemia
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(21.3 %) discontinued study drugs prematurely because of
adverse events. However, there was no adverse event-related
death in both groups and 3 and 4 patients died of fatal infec-
tions in the micafungin and itraconazole group, respectively.
Discussion
This randomized, multicenter trial has shown that empirical
micafungin is as effective as itraconazole for patients with
febrile neutropenia. Micafungin compares favorably with
itraconazole in terms of overall success rates and toxicity
profiles. Theoretically, the echinocandins have advantages
over the azole or polyene compounds as empirical therapy
because of their wide coverage and high efficacy against
invasive aspergillosis [7, 8]. The efficacy and safety of the
echinocandins as empirical antifungal therapy were
demonstrated with caspofungin by Walsh et al. [17]. When
compared to liposomal amphotericin B, caspofungin showed
favorable efficacy and a better toxicity profile and tolerance.
Micafungin is another new echinocandin that has considerable
efficacy and a notable toxicity profile [11, 12, 19, 20]. We
previously investigated the possible efficacy and safety of
micafungin as an empirical therapy in febrile neutropenia with
a small observational study [13]. However, there has been no
randomized study to compare micafungin with other agents as
empirical therapy. As far as we know, this is the first random-
ized study of micafungin as empirical therapy in febrile neu-
tropenia. Since itraconazole has been the only drug allowed
for empirical therapy in Korea since 2005, we had to compare
micafungin with itraconazole in this study.
In this study, the overall success rate evaluated with five
composite scores was somewhat higher (64.4 % for the
micafungin group and 57.2 % for the itraconazole group) than
that of previous studies on empirical therapy with liposomal
amphotericin, voriconazole, and caspofungin [17, 21, 22]. In
this study, the patients started empirical antifungal drugs
earlier than those in previous studies when they had
sustained fever more than 72 h despite proper antibiotics
therapy, whereas 96–120 h in other studies. Another pos-
sible explanation is that the patients undergoing hemato-
poietic stem cell transplantation (HSCT) were not included
in this study unlike other empirical trials, since micafungin
was allowed to be used as prophylactic therapy for HSCT
in Korea.
Breakthrough fungal infection occurred in 3 patients (4 %)
in the micafungin group. One patient was proven to have
systemic Candida infection. Although micafungin has
Fig. 2 Duration of fever (a) and hospital stay (b)
Table 3 The treatment outcome of baseline fungal infection
Study group Documented fungi Resolution Resolution rate
Micafungin Aspergillus flavus
Candida albicans
Candida tropicalis
Candida spp.
Trichosporon asahii
1/1
2/2
1/2
0/1
0/1
57.1 %
Itraconazole Aspergillus spp.
Candida albicans
Candida tropicalis
Candida spp.
1/3
2/4
1/1
1/1
55.6 %
All of the fungi were documented within 2 days of the initiation of study
drugs
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potent activity against Candida spp. and Aspergillus spp.,
recent research has shown that breakthrough IFI occurred
most commonly due to Candida spp. for high minimum
inhibitory concentration and/or relative insensitivity to
echinocandins [23]. Thus, systemic candidemia should be
considered when the patients show clinical aggravation
despite micafungin treatment.
Another strength of this study is that the study popula-
tion consists of homogeneous patients undergoing inten-
sive chemotherapy for hematological malignancies where
anticipated mortality from IFIs is the highest. Although
some studies pursued a preemptive strategy with recent ad-
vances of sensitive mycological tests and imaging techniques
[24, 25], the most effective strategy in preventing or treating
invasive fungal disease in febrile neutropenia is still under
debate. Since the mortality from IFIs is considerable in pa-
tients with acute leukemia suffering from febrile neutropenia,
especially while undergoing induction chemotherapy, empiri-
cal therapy is still widely accepted in this clinical setting [26].
This study showed the efficacy of micafungin as an empirical
therapy option in this high-risk population.
Duration of hospital stay was adopted as an indication of
the overall effectiveness of empirical antifungal treatment. It
could be a good surrogate for the combined results of treat-
ment success, adverse effects, and other clinical aspects. The
duration of neutropenia was not different between the two
groups, and duration of fever was only modestly shorter in
the micafungin group. However, the duration of hospitaliza-
tion was shorter in the micafungin group bymedian 5 days (22
vs. 27 days, p=0.033). This may benefit patients because it
allows treatment to progress to the next step in a timely man-
ner and dose intensity can be maintained throughout the entire
treatment while treatment costs can also be decreased.
Although not proven in this study, this may be translated to
a better long-term treatment outcome. Considering the shorter
hospital stay, micafungin seems to have advantages over
itraconazole despite no significant difference in the overall
success rate by a composite score between the two groups.
In summary, micafungin was effective as empirical therapy
in sustained fever and neutropenia with acceptable toxicity
profiles in comparison with itraconazole. Additionally, it sig-
nificantly decreased the duration of hospitalization when com-
pared to itraconazole. Among available antifungal agents,
micafungin could be a favorable option for empirical antifun-
gal treatment in febrile neutropenia.
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Table 4 Adverse events
Adverse events Micafungin (n=73) Itraconazole (n=75)
All grades (n) Grade III–IV (n) All grades (n) Grade III–IV (n)
Hyperbilirubinemia
Elevation of transaminase level
Electrolyte imbalance
Atrial fibrillation
Anaphylaxis
Delirium
Insomnia
Skin rash
10
5
18
1
1
3
4
9
2
2
1
1
1
0
0
0
11
19
16
0
0
2
1
5
7
4
2
0
0
0
0
0
Total 51 11 44 17
Probability of grade 3 ormore severe adverse events was not different between the two groups. Each case of atrial
fibrillation and anaphylaxis occurred in the micafungin group, which should be reminded prudently despite the
fact that the events were well controlled with medications
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